Cytek Biosciences, Inc. (CTKB) vs Gyre Therapeutics, Inc. (GYRE)
A side-by-side comparison of Cytek Biosciences, Inc. and Gyre Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTKB
Cytek Biosciences, Inc.
$5.98HealthcareDelayed quote: Oct 6, 2026, 10:00 AM EDT
GYRE
Gyre Therapeutics, Inc.
$7.25HealthcareDelayed quote: Oct 6, 2026, 10:00 AM EDT
Total return — CTKB vs GYRE
growth of $100 · dividends reinvested · last 5yCTKB -67.5% (-20.1%/yr)GYRE -15.6% (-3.3%/yr)GYRE compounded faster over this window
CTKB GYRE
CTKB vs GYRE: by the numbers
- •GYRE is the larger company ($808M vs $772M market cap).
- •Both run net losses; GYRE's is the smaller (-14.52% vs -38.98% net margin).
- •GYRE grew revenue faster over the past five years (84.92% vs 13.37% CAGR).
Metrics side by side
Valuation
| Metric | CTKB | GYRE |
|---|---|---|
| P/S ratio | 3.74 | 6.77 |
| P/B ratio | 2.40 | 7.49 |
Profitability
| Metric | CTKB | GYRE |
|---|---|---|
| Gross margin | 53.23% | 94.30% |
| Operating margin | -21.60% | 9.86% |
| Net margin | -38.98% | -14.52% |
| ROE | -25.03% | -13.30% |
| ROIC | -12.00% | -9.77% |
Growth (annualized)
| Metric | CTKB | GYRE |
|---|---|---|
| Revenue CAGR (5Y) | 13.37% | 84.92% |
| Total return CAGR (5Y) | -23.16% | -0.34% |
Frequently asked
- Which has grown faster, CTKB or GYRE?
- Over the past five years, GYRE grew revenue faster — CTKB at a 13.37% CAGR versus GYRE at 84.92%.
- How have CTKB and GYRE total returns compared?
- Over the past 5 years, CTKB delivered -23.16% and GYRE delivered -0.34% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Cytek Biosciences ROEGyre Therapeutics ROECytek Biosciences operating marginGyre Therapeutics operating marginCytek Biosciences revenue growthGyre Therapeutics revenue growthCytek Biosciences free cash flowGyre Therapeutics free cash flow
Cytek Biosciences & Gyre Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.